Edition:
United States

Momenta Pharmaceuticals Inc (MNTA.OQ)

MNTA.OQ on NASDAQ Stock Exchange Global Select Market

13.05USD
14 Dec 2017
Change (% chg)

$-0.30 (-2.25%)
Prev Close
$13.35
Open
$13.30
Day's High
$13.45
Day's Low
$12.88
Volume
242,915
Avg. Vol
206,124
52-wk High
$19.90
52-wk Low
$11.85

Latest Key Developments (Source: Significant Developments)

Momenta Pharma says Q3 loss per share $0.44
Wednesday, 1 Nov 2017 08:05am EDT 

Nov 1 (Reuters) - Momenta Pharmaceuticals Inc -:Momenta Pharmaceuticals reports third quarter 2017 financial results and provides corporate update.Q3 revenue $24.1 million versus $29.1 million.Q3 revenue view $30.6 million -- Thomson Reuters I/B/E/S.Q3 loss per share $0.44.Q3 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S.Momenta Pharmaceuticals - co and Mylan are targeting a first regulatory submission for clinical development of M710 by early 2018​.Momenta Pharmaceuticals - ‍updated non-GAAP operating expense guidance of about $200 million - $210 million for 2017 and $43 million - $53 million for Q4 of 2017​.Momenta Pharmaceuticals Inc - ‍expects to recognize $50 million upfront payment from CSL as revenue in Q4 of 2017​.Momenta Pharmaceuticals Inc - ‍estimates that collaborative reimbursement revenues will be approximately $0 - $2 million in Q4 of 2017​.  Full Article

Momenta And Mylan report initial results from phase 1 clinical trial for M834
Wednesday, 1 Nov 2017 08:00am EDT 

Nov 1 (Reuters) - Momenta Pharmaceuticals Inc :Momenta And Mylan report initial results from phase 1 clinical trial for M834, a proposed biosimilar of Orencia® (abatacept).Mylan NV - ‍M834, a proposed biosimilar of Orencia (Abatacept), did not meet its primary pharmacokinetic (PK) endpoints in phase 1 study​.Mylan NV - ‍Momenta And Co continue to gather and analyze data to inform next steps for M834 program ​.  Full Article

Momenta Pharmaceuticals posts Q2 loss per share $0.50
Wednesday, 2 Aug 2017 08:00am EDT 

Aug 2 (Reuters) - Momenta Pharmaceuticals Inc ::Momenta pharmaceuticals reports second quarter 2017 financial results and provides corporate update.Q2 revenue $23.5 million versus I/B/E/S view $24.6 million.Q2 loss per share $0.50.Q2 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.Momenta pharmaceuticals inc - ‍remain optimistic that co could see a potential glatopa 40 mg approval and launch into marketplace in 2017 timeframe​.Momenta pharmaceuticals inc - ‍updated non-GAAP operating expense guidance of approximately $210 - $230 million for 2017 and $50 - $60 million for Q3​.Momenta pharmaceuticals inc - company continues to expect to recognize revenue from Mylan's $45 million upfront payment on a quarterly basis.Momenta pharmaceuticals inc - also expects to recognize $10 million glatopa 20 mg milestone as revenue in q3 of 2017.Momenta pharmaceuticals inc - also expects to recognize $50 million upfront payment from csl as revenue in q4 of 2017.Momenta pharmaceuticals - at june 30, 2017, co had $456.8 million in cash, cash equivalents and marketable securities compared to $433.7 million at march 31, 2017.  Full Article

Amphastar announces jury verdict in litigation against Momenta Pharmaceuticals and Sandoz Inc
Monday, 24 Jul 2017 06:00am EDT 

July 24 (Reuters) - Amphastar Pharmaceuticals Inc :Amphastar announces jury verdict in patent litigation against Momenta Pharmaceuticals Inc and Sandoz Inc.Amphastar Pharmaceuticals - ‍jury found claims of Momenta's U.S. patent to be "invalid for lack of enablement and lack of adequate written description"​.  Full Article

Momenta Pharmaceuticals says U.S. court found its patent for manufacturing LOVENOX "was infringed"
Friday, 21 Jul 2017 02:16pm EDT 

July 21 (Reuters) - Momenta Pharmaceuticals Inc ::Momenta Pharmaceuticals announces jury verdict in Enoxaparin Sodium Injection patent litigation against Amphastar.U.S. court issued verdict finding that co's U.S. patent covering methods for manufacturing of generic LOVENOX "was infringed".  Full Article

Momenta Pharmaceuticals Q1 loss per share $0.46
Tuesday, 2 May 2017 08:00am EDT 

May 2 (Reuters) - Momenta Pharmaceuticals Inc :Momenta pharmaceuticals reports first quarter 2017 financial results.Q1 revenue $26.6 million versus i/b/e/s view $24.5 million.Q1 loss per share $0.46.Q1 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S.Momenta pharmaceuticals says reiterating non-gaap operating expense guidance of approximately $200 - $240 million for 2017 and $50 - $60 million for q2 of 2017.Says expects to recognize $50 million upfront payment from csl as revenue in second half of 2017.  Full Article

Momenta Pharmaceuticals says U.S. Court of Appeals reversed district court's dismissal filed by Amphastar Pharma against Co
Wednesday, 8 Mar 2017 09:01am EST 

Amphastar Pharmaceuticals Inc : Momenta Pharmaceuticals- on March 6, U.S. Court of Appeals for first circuit reversed district court's dismissal filed by Amphastar Pharma against Co .Momenta Pharmaceuticals- suit by Amphastar against Co alleged Momenta, Sandoz sought to prevent Amphastar from selling generic enoxaparin sodium injection.  Full Article

Momenta Pharmaceuticals Q4 earnings per share $0.60
Tuesday, 21 Feb 2017 07:00am EST 

Momenta Pharmaceuticals Inc : Momenta Pharmaceuticals reports fourth quarter and year end 2016 financial results . Q4 earnings per share $0.60 . Q4 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S . Qtrly total collaboration revenue $ 34.2 million versus $22.4 million .Momenta Pharmaceuticals-sees 2017 non-gaap operating expense guidance of about $200 - $240 million; sees q1 non-gaap operating expense to be $50 - $60 million.  Full Article

Momenta Pharmaceuticals announces FDA warning letter to contracted Glatopa
Friday, 17 Feb 2017 07:02pm EST 

Momenta Pharmaceuticals Inc : Momenta Pharmaceuticals announces FDA warning letter to contracted glatopa (glatiramer acetate injection) fill/finish manufacturer . Momenta Pharmaceuticals Inc - approval of glatopa 40 mg ANDA will be dependent on resolution of Pfizer facility compliance issues . Momenta Pharmaceuticals Inc - warning letter does not restrict production or shipment of glatopa 20 mg . Momenta Pharmaceuticals Inc - company believes application review could be completed at any time . Momenta Pharmaceuticals Inc - Momenta expects that an approval in Q1 of 2017 is unlikely . Momenta - working with collaboration partner Sandoz to resolve this matter in order to allow for an ANDA approval as soon as possible .Momenta Pharmaceuticals - Pfizer indicated warning letter does not restrict production, shipment of glatopa 20 mg product currently marketed by Sandoz in U.S..  Full Article

Momenta Pharmaceuticals announces FDA warning letter to contracted Glatopa
Friday, 17 Feb 2017 06:00pm EST 

Momenta Pharmaceuticals Inc : Momenta Pharmaceuticals announces FDA warning letter to contracted glatopa (glatiramer acetate injection) fill/finish manufacturer . Momenta Pharmaceuticals Inc - approval of glatopa 40 mg ANDA will be dependent on resolution of Pfizer facility compliance issues . Momenta Pharmaceuticals Inc - warning letter does not restrict production or shipment of glatopa 20 mg . Momenta Pharmaceuticals Inc - company believes application review could be completed at any time . Momenta Pharmaceuticals Inc - Momenta expects that an approval in Q1 of 2017 is unlikely . Momenta - working with collaboration partner Sandoz to resolve this matter in order to allow for an ANDA approval as soon as possible .Momenta Pharmaceuticals - Pfizer indicated warning letter does not restrict production, shipment of glatopa 20 mg product currently marketed by Sandoz in U.S..  Full Article

BRIEF-Momenta Pharma says Q3 loss per share $0.44

* Momenta Pharmaceuticals reports third quarter 2017 financial results and provides corporate update